IP Library › Granted Patent US 12,370,148
Granted Patent B2
US 12,370,148 · App. 18/421,205 · Granted Jul 29, 2025

Orally ingestible delivery system

Inventors: David S. Soane (Coral Gables, FL); Allison H. Greene (Reno, NV); Alexander V. Soane (Coral Gables, FL)
Assignee: Soane Pharma LLC
A61K9/4816A61K9/0053A61K9/4808A61K35/12A61K36/00A61K38/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,370,148
App. No.
18/421,205
Granted
Jul 29, 2025
Kind
B2
Abstract

The invention includes an orally ingestible delivery system for releasing a therapeutic agent within an intestine of a mammal, where the system includes the therapeutic agent and a differentially permeable capsule system containing the therapeutic agent within a therapeutic agent compartment, with the differentially permeable capsule system dimensionally adapted for oral ingestion and for passage into a stomach of the mammal and thence into the intestine, wherein the differentially permeable capsule system comprises an acid-resistant shell and a dispersible acid barrier, wherein the dispersible acid barrier forms while the orally-ingestible delivery system is in the stomach; and wherein the dispersible acid barrier is dispersed in the intestine, thereby permitting enzymes in the intestine to reach the therapeutic agent compartment. The invention also includes methods of manufacturing the system and methods for its use.

Claims (20)

1. An orally ingestible delivery system for releasing a therapeutic agent within an intestine of a mammal, comprising:

the therapeutic agent and a differentially permeable capsule system containing the therapeutic agent within a therapeutic agent compartment,

wherein the differentially permeable capsule system is dimensionally adapted for oral ingestion and for passage into a stomach of the mammal and thence into the intestine;

wherein the differentially permeable capsule system comprises an acid-resistant protease-digestible membrane and a carbonate;

wherein the acid-resistant protease-digestible membrane comprises an inner protease-digestible layer and an outer acid-resistant layer,

wherein the inner protease-digestible layer surrounds the therapeutic agent compartment;

wherein the outer acid-resistant layer is perforated by a system of pores providing fluid communication between the external surface of the acid-resistant protease-digestible membrane and the inner protease-digestible layer, and wherein the carbonate is contained within the system of pores;

wherein the carbonate reacts with stomach acid to form a dispersible acid barrier,

wherein the dispersible acid barrier is carbon dioxide gas and is formed within the pores and on the exterior surface of the outer acid-resistant layer, and wherein the dispersible acid barrier inhibits contact between the acid-resistant protease-digestible membrane and the gastric juice of the stomach.

2. The system of claim 1 , wherein the therapeutic agent is a protein or a peptide.

3. The system of claim 1 , wherein the therapeutic agent is a living organism.

4. The system of claim 1 , wherein the carbonate is selected from the group consisting of calcium carbonate, sodium bicarbonate, potassium bicarbonate, and magnesium carbonate.

5. The system of claim 1 , wherein the inner protease-digestible layer comprises gelatin.

6. The system of claim 1 , wherein the carbonate is solid bicarbonate.

7. The system of claim 1 , wherein the therapeutic agent is a prebiotic.

8. The system of claim 1 , wherein the therapeutic agent is a probiotic.

9. The system of claim 1 , wherein therapeutic agent is a small molecule.

10. The system of claim 1 , wherein the system of pores is an interconnected system of pores.

11. The system of claim 1 , wherein the outer acid-resistant layer comprises a wax.

12. The system of claim 1 , wherein the wax is selected from the group consisting of beeswax, soybean wax, and carnauba wax.

Continuity (8)
Division 17075030 · Oct 20, 2020
Provisional Application 63088070 · Oct 6, 2020
Provisional Application 63058231 · Jul 29, 2020
Provisional Application 63010132 · Apr 15, 2020
Provisional Application 62981651 · Feb 26, 2020
Provisional Application 62950527 · Dec 19, 2019
Provisional Application 62923783 · Oct 21, 2019
Related Publication 20240342100A1 · Oct 17, 2024
References Cited (20)
US 20090214600A1 · Debrouse · 2009 [cited by applicant]
US 20110182954A1 · Takahashi et al. · 2011 [cited by applicant]
US 20180221286A1 · Kabadi et al. · 2018 [cited by applicant]
EP 2832352A1 · 2015 [cited by applicant]
WO 2010035656A1 · 2010 [cited by applicant]
WO 2014013006A1 · 2014 [cited by applicant]
Choi, B. Y., et al. “Preparation of alginate beads for floating drug delivery system: effects of CO2 gas-forming agents.” International journal of pharmaceutics 239.1-2 (2002): 81-91. (Year: 2002). [cited by examiner]
Hsu, Bryan B., et al. “In situ reprogramming of gut bacteria by oral delivery.” Nature communications 11.1 (2020): 5030. (Year: 2020). [cited by examiner]
Chávarri, María, et al. “Microencapsulation of a probiotic and prebiotic in alginate-chitosan capsules improves survival in simulated gastro-intestinal conditions.” International journal of food microbiology 142.1-2 (20… [cited by examiner]
Shi, Lu-E., et al. “Encapsulation of Lactobacillus bulgaricus in carrageenan-locust bean gum coated milk microspheres with double layer structure.” LWT-Food Science and Technology 54.1 (2013): 147-151. (Year: 2013). [cited by examiner]
Kim, Jeong Un, et al. “Encapsulation of probiotic Lactobacillus acidophilus by ionic gelation with electrostatic extrusion for enhancement of survival under simulated gastric conditions and during refrigerated storage.”… [cited by examiner]
Fatih Ozogul, Imen Hamed, Lactic Acid Bacteria: [cited by examiner]
“Gas in the Digestive Tract”, Wake Gastroenterology. Retrieved on May 17, 2023, online at https://wakegastro.com/patient-info/patient-education/gas-in-the-digestive-tract, 7 pgs. [cited by applicant]
“Intestinal Gas”, Retrieved on May 17, 2023, online at https://www.britannica.com/science/intestinal-gas, 5 pgs. [cited by applicant]
Choi, B. , et al., “Preparation of Alginate Beads for Floating Drug Delivery System: Effects of CO2 Gas-Forming Agents”, Int. J. Pharmaceut., vol. 239, Feb. 4, 2002, 81-91. [cited by applicant]
Garg, V. , et al., “Antacids revisited: review on contemporary facts and relevance for self-management”, J. Int. Med. Res., 50(3), Mar. 2022, 1-22. [cited by applicant]
Ichikawa, M. , et al., “A New Multiple-Unit Oral Floating Dosage System. I: Preparation and In Vitro Evaluation of Floating and Sustained-Release Characteristics”, J. Pharmaceut. Sci., 80(11), Nov. 1991, 1062-1066. [cited by applicant]
Le, J. , “Drug Absorption”, Merck Manual Professional Version. Retrieved on May 17, 2023, online at https://www.merckmanuals.com/professional/clinical-pharmacology/pharmacokinetics/drug-absorption. Modified Sep. 2022, 5… [cited by applicant]
Nokhodchi, A. , et al., “The Role of Oral Controlled Release Matrix Tablets in Drug Delivery Systems”, Biolmpacts, 2(4), 2012, 175-187. [cited by applicant]
Rouge, N. , et al., “Buoyancy and Drug Release Paterns of Floating Minitablets Containing Pretanide and Atenolol as Model Drugs”, Pharmaceut. Dev. and Tech., 3(1), 1998, 73-84. [cited by applicant]